Introduction: Relapses are important contributors to illness and morbidity in Plasmodium
vivax and P. ovale infections. Relapse prevention (radical cure) with primaquine is required …

Background Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but
the optimum duration of treatment and best partner drug are uncertain. A randomized …

Background Vivax malaria remains a major cause of morbidity in the subtropics. To
undermine the stability of the disease, drugs are required that prevent relapse and provide …

Background Primaquine has been the only widely available hypnozoitocidal anti-malarial
drug for half a century. Despite this its clinical efficacy is poorly characterized resulting in a …

Plasmodium vivax causes debilitating but usually non-lethal malaria in most of Asia and
South America. Prevention of relapse after otherwise effective therapy for the acute attack …

The incidence and range of endemic malaria caused by Plasmodium vivax has expanded
during the past 30 years. This parasite forms hypnozoites in the liver, creating a persistent …

Plasmodium vivax and Plasmodium ovale form dormant liver hypnozoites that can reactivate
weeks to months following initial infection. Malaria recurrences caused by relapses are an …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

In regions coendemic for P. vivax and P. falciparum, a unified treatment policy for malaria of
any parasitological cause is likely to confer the greatest individual and public health benefit …

Background In most of the Americas, the recommended treatment to prevent relapse of
Plasmodium vivax malaria is primaquine at a total dose of 3.5 mg per kilogram of body …